Advertisement

Journal of Zhejiang University SCIENCE B

, Volume 14, Issue 6, pp 460–467 | Cite as

Down-regulation of eIF5A-2 prevents epithelial-mesenchymal transition in non-small-cell lung cancer cells

  • Guo-dong Xu
  • Xin-bao Shi
  • Le-bo Sun
  • Qing-yun Zhou
  • Da-wei Zheng
  • Huo-shun Shi
  • Yong-liang Che
  • Zi-shan Wang
  • Guo-feng Shao
Article

Abstract

Background

Epithelial-mesenchymal transition (EMT) is believed to be the critical process in malignant tumor invasion and metastases, and has a great influence on improving the survival rate in non-small-cell lung cancer (NSCLC) patients. Recent studies suggested that eukaryotic initiation factor 5A-2 (eIF5A-2) might serve as an adverse prognostic marker of survival. We detected eIF5A-2 in NSCLC A549 cells, and found that the invasive capability correlates with the eIF5A-2 expression.

Methods

Transforming growth factor (TGF)-β1 was used to induce EMT in A549 cells. Western blotting, immunofluorescence, wound healing assay, and transwell-matrigel invasion chambers were used to identify phenotype changes. Western blotting was also used to observe changes of the expression of eIF5A-2. We down-regulated the eIF5A-2 expression using an eIF5A-2 siRNA and identified the phenotype changes by western blotting and immunofluorescence. We tested the change of migration and invasion capabilities of A549 cells by the wound healing assay and transwell-matrigel invasion chambers.

Results

After stimulating with TGF-β1, almost all A549 cells changed to the mesenchymal phenotype and acquired more migration and invasion capabilities. These cells also had higher eIF5A-2 protein expression. Down-regulation of eIF5A-2 expression with eIF5A-2 siRNA transfection could change the cells from mesenchymal to epithelial phenotype and decrease tumor cell migration and invasive capabilities significantly.

Conclusions

The expression of eIF5A-2 was up-regulated following EMT phenotype changes in A549 cells, which correlated with enhanced tumor invasion and metastatic capabilities. Furthermore, in the A549 cell line, the process of EMT phenotype change could be reversed by eIF5A-2 siRNA, with a consequent weakening of both invasive and metastatic capabilities.

Key words

Non-small-cell lung cancer (NSCLC) Epithelial-mesenchymal transition (EMT) Eukaryotic initiation factor 5A-2 (eIF5A-2) Transforming growth factor (TGF)-β1 A549 

CLC number

R734.2 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chen, W., Luo, J.H., Hua, W.F., Zhou, F.J., Lin, M.C., Kung, H.F., Xie, D., 2009. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Epidemiol. Biomarkers Prev., 18(2):400–408. [doi:10.1158/1055-9965.EPI-08-0754]PubMedCrossRefGoogle Scholar
  2. Clement, P.M., Hanauske-Abel, H.M., Wolff, E.C., Kleinman, H.K., Park, M.H., 2002. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int. J. Cancer, 100(4):491–498. [doi:10.1002/ijc.10515]PubMedCrossRefGoogle Scholar
  3. Clement, P.M., Henderson, C.A., Jenkins, Z.A., Smit-McBride, Z., Wolff, E.C., Hershey, J.W., Johansson, H.E., 2003. Identification and characterization of eukaryotic initiation factor 5A-2. Eur. J. Biochem., 270(21):4254–4263. [doi:10.1046/j.1432-1033.2003.03806.x]PubMedCrossRefGoogle Scholar
  4. Clement, P.M., Johansson, H.E., Wolff, E.C., Park, M.H., 2006. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J., 273(6):1102–1114. [doi:10. 1111/j.1742-4658.2006.05135.x]PubMedCrossRefGoogle Scholar
  5. Grünert, S., Jechlinger, M., Beug, H., 2003. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol., 4(8): 657–665. [doi:10.1038/nrm1175]PubMedCrossRefGoogle Scholar
  6. Guan, X.Y., Fung, J.M., Ma, N.F., Lau, S.H., Tai, L.S., Xie, D., Sham, J.S., 2004. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res., 64(12): 4197–4200. [doi:10.1158/0008-5472.CAN-03-3747]PubMedCrossRefGoogle Scholar
  7. He, L.R., Zhao, H.Y., Li, B.K., Liu, Y.H., Liu, M.Z., Guan, X.Y., Xie, D., 2011. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. Int. J. Cancer, 129(1):143–150. [doi:10.1002/ijc.25669]PubMedCrossRefGoogle Scholar
  8. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., Thun, M.J., 2008. Cancer statistics, 2008. CA Cancer J. Clin., 58(2):71–96. [doi:10.3322/CA.2007.0010]PubMedCrossRefGoogle Scholar
  9. Kasai, H., Allen, J.T., Mason, R.M., Kamimura, T., Zhang, Z., 2005. TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res., 6(1):56. [doi:10.1186/1465-9921-6-56]PubMedCrossRefGoogle Scholar
  10. Kim, J.H., Jang, Y.S., Eom, K.S., Hwang, Y.I., Kang, H.R., Jang, S.H., Kim, D.G., 2007. Transforming growth factor β1 induces epithelial-to-mesenchymal transition of A549 cells. J. Korean Med. Sci., 22(5):898–904. [doi:10.3346/jkms.2007.22.5.898]PubMedCrossRefGoogle Scholar
  11. Li, A.L., Li, H.Y., Jin, B.F., Ye, Q.N., Zhou, T., Yu, X.D., Zhang, X.M., 2004. A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J. Biol. Chem., 279(47):49251–49258. [doi:10.1074/jbc.M407165200]PubMedCrossRefGoogle Scholar
  12. Maitah, M.Y., Ali, S., Ahmad, A., Gadgeel, S., Sarkar, F.H., 2011. Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One, 6(1):e16068. [doi:10.1371/journal.pone.0016068]PubMedCrossRefGoogle Scholar
  13. Nishimura, K., Murozumi, K., Shirahata, A., Park, M.H., Kashiwagi, K., Igarashi, K., 2005. Independent roles of eIF5A and polyamines in cell proliferation. Biochem. J., 385(Pt3):779–785. [doi:10.1042/BJ20041477]PubMedGoogle Scholar
  14. Nozawa, N., Hashimoto, S., Nakashima, Y., Matsuo, Y., Koga, T., Sugio, K., Sueishi, K., 2006. Immunohistochemical α- and β-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol. Res. Pract., 202(9):639–650. [doi:10.1016/j. prp.2006.03.007]PubMedCrossRefGoogle Scholar
  15. Rosell, R., Felip, E., Taron, M., Majo, J., Mendez, P., Sanchez-Ronco, M., Maestre, J., 2004. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res., 10(12):4215s–4219s. [doi:10.1158/1078-0432.CCR-040006]PubMedCrossRefGoogle Scholar
  16. Saito, R.A., Watabe, T., Horiguchi, K., Kohyama, T., Saitoh, M., Nagase, T., Miyazono, K., 2009. Thyroid transcription factor-1 inhibits transforming growth factor-β-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res., 69(7):2783–2791. [doi:10.1158/0008-5472.CAN-08-3490]PubMedCrossRefGoogle Scholar
  17. Tang, D.J., Dong, S.S., Ma, N.F., Xie, D., Chen, L., Fu, L., Guan, X.Y., 2010. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology, 51(4):1255–1263. [doi:10.1002/hep.23451]PubMedCrossRefGoogle Scholar
  18. Thiery, J.P., 2002. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2(6):442–454. [doi:10.1038/nrc822]PubMedCrossRefGoogle Scholar
  19. Wozniak, A.J., Gadgeel, S.M., 2007. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further? Oncology, 21(2):163–171.PubMedGoogle Scholar
  20. Xie, D., Ma, N.F., Pan, Z.Z., Wu, H.X., Liu, Y.D., Wu, G.Q., Guan, X.Y., 2008. Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma. Hum. Pathol., 39(1):80–86. [doi:10.1016/j.humpath.2007.05.011]PubMedCrossRefGoogle Scholar
  21. Yang, G.F., Xie, D., Liu, J.H., Luo, J.H., Li, L.J., Hua, W.F., Guan, X.Y., 2009. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecol. Oncol., 112(2):314–318. [doi:10.1016/j.ygyno.2008.10.024]PubMedCrossRefGoogle Scholar

Copyright information

© Zhejiang University and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Guo-dong Xu
    • 1
  • Xin-bao Shi
    • 1
  • Le-bo Sun
    • 1
  • Qing-yun Zhou
    • 1
  • Da-wei Zheng
    • 1
  • Huo-shun Shi
    • 1
  • Yong-liang Che
    • 1
  • Zi-shan Wang
    • 2
  • Guo-feng Shao
    • 1
  1. 1.Department of Thoracic & Cardiovascular Surgery, Lihuili Hospital, Ningbo Medical Center, Affiliated Hospital of Medical SchoolNingbo UniversityNingboChina
  2. 2.Department of Thoracic & Cardiovascular Surgery, Ningbo First Hospital, Affiliated Hospital of Medical SchoolNingbo UniversityNingboChina

Personalised recommendations